Roles of Pharmacists in the Management of Sickle Cell Disease in Adults: A Narrative Review
- PMID: 38525091
- PMCID: PMC10959085
- DOI: 10.1177/87551225231222437
Roles of Pharmacists in the Management of Sickle Cell Disease in Adults: A Narrative Review
Abstract
Background: Sickle cell disease (SCD) is an autosomal, recessive, genetic condition of the sickle cell genes. It affects about 100 000 people in the United States where an estimated 1 out of every 365 black children and 1 out of every 13 black children will be born with SCD and sickle cell trait, respectively. Severe and unpredictable pain crisis are the leading cause of emergency department visit for adult patients with SCD and account for 90% of inpatient hospitalizations and 85% of all acute medical care, as well as high usage of medical resources. The care of patients with SCD is complex and requires a multidisciplinary approach. With a few pharmacotherapeutic options to reduce SCD complications and pain episodes, the role of pharmacists in the medication management is unclear. This article aims to outline the potential role of pharmacists in SCD management. Data sources: The authors searched Medline, PubMed, EMBASE, and Scopus from January 1, 1990 to August 31, 2022, for primary literature that assessed the role of pharmacists in managing patients with SCD. Results: The authors identified relevant studies and summarized the role of pharmacists in SCD management. Conclusions: Access to comprehensive health care is essential to ensure that patients with SCD have decreased hospitalizations and good health-related quality of life. Pharmacists are an integral part of the multidisciplinary health-care team and can help patients with SCD navigate the complexities of health care. Pharmacists are medication experts who are positioned to ensure comprehensive care in the acute and chronic SCD management.
Keywords: adults; management; pharmacists; role; sickle cell disease (SCD).
© The Author(s) 2024.
Conflict of interest statement
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Similar articles
-
Surveillance for Sickle Cell Disease - Sickle Cell Data Collection Program, Two States, 2004-2018.MMWR Surveill Summ. 2022 Oct 7;71(9):1-18. doi: 10.15585/mmwr.ss7109a1. MMWR Surveill Summ. 2022. PMID: 36201430 Free PMC article.
-
Pharmacological interventions for painful sickle cell vaso-occlusive crises in adults.Cochrane Database Syst Rev. 2019 Nov 14;2019(11):CD012187. doi: 10.1002/14651858.CD012187.pub2. Cochrane Database Syst Rev. 2019. PMID: 31742673 Free PMC article.
-
Transcutaneous electrical nerve stimulation (TENS) for pain management in sickle cell disease.Cochrane Database Syst Rev. 2020 Mar 3;3(3):CD012762. doi: 10.1002/14651858.CD012762.pub2. Cochrane Database Syst Rev. 2020. PMID: 32124977 Free PMC article.
-
Orofacial Manifestation and Dental Management of Sickle Cell Disease: A Scoping Review.Anemia. 2021 Oct 22;2021:5556708. doi: 10.1155/2021/5556708. eCollection 2021. Anemia. 2021. PMID: 34721900 Free PMC article.
-
Hospitalization Events Among Adolescents and Adults With Sickle Cell Disease in a Tertiary Care Center in Central India.Cureus. 2024 May 27;16(5):e61185. doi: 10.7759/cureus.61185. eCollection 2024 May. Cureus. 2024. PMID: 38933640 Free PMC article.
References
-
- Brousseau DC, Panepinto JA, Nimmer M, Hoffmann RG. The number of people with sickle-cell disease in the United States: national and state estimates. Am J Hematol. 2010;85(1):77-78. - PubMed
-
- Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet. 2010;376(9757):2018-2031. - PubMed
-
- Centers for Disease Control and Prevention. Sickle Cell Disease (SCD). www.cdc.gov/ncbddd/sicklecell/data.html. Accessed September 1, 2023.
-
- McCavit TL. Sickle cell disease. Pediatr Rev. 2012;33:195-204. - PubMed
Publication types
LinkOut - more resources
Full Text Sources